Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CGTX
$1.115
$
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Next Earnings
2026-02-25
Beta
1.249
Average Volume
Market Cap
Last Dividend
CIK
0001455365
ISIN
US19243B1026
CUSIP
19243B102
CEO
Lisa Ricciardi
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
25
IPO Date
2021-10-08
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB). The program, which was originally expected to provide each participant with twelve months of treatment, will now allow several more months of treatment. | GlobeNewsWire | 2026-02-05 07:30:00 |
| Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies | PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food and Drug Administration (FDA) on January 21, 2026. The objective of this meeting was to review plans for the proposed Phase 2b study of zervimesine in dementia with Lewy bodies (DLB), a disease with no FDA-approved therapies. | GlobeNewsWire | 2026-01-27 07:30:00 |
| Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies | - Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo - - Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo - | GlobeNewsWire | 2026-01-06 07:30:00 |
| Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference | - Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting - - Actively Evaluating Strategy Across DLB and Alzheimer's Disease - | GlobeNewsWire | 2025-12-01 07:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 8-K | 2026-01-27 | 2026-01-27 | View Filing |
| EFFECT | 2025-12-23 | 2025-12-29 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 8-K | 2025-12-18 | 2025-12-18 | View Filing |
| S-3 | 2025-12-18 | 2025-12-18 | View Filing |
| 10-Q | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| SC 13D/A | 2025-09-23 | 2025-09-23 | View Filing |
| 4 | 2025-09-23 | 2025-09-23 | View Filing |
| 8-K | 2025-09-15 | 2025-09-15 | View Filing |
| 8-K | 2025-08-28 | 2025-08-28 | View Filing |
| 424B5 | 2025-08-28 | 2025-08-28 | View Filing |
| 8-K | 2025-08-26 | 2025-08-26 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| 8-K | 2025-06-20 | 2025-06-20 | View Filing |
| 8-K | 2025-06-03 | 2025-06-03 | View Filing |
| 8-K | 2025-06-02 | 2025-06-02 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| 10-Q | 2025-05-07 | 2025-05-07 | View Filing |
| 8-K | 2025-05-07 | 2025-05-07 | View Filing |
| 4 | 2025-05-02 | 2025-05-02 | View Filing |
| ARS | 2025-04-28 | 2025-04-28 | View Filing |
| DEFA14A | 2025-04-28 | 2025-04-28 | View Filing |
| DEF 14A | 2025-04-28 | 2025-04-28 | View Filing |
| 424B5 | 2025-03-20 | 2025-03-20 | View Filing |
| S-8 | 2025-03-20 | 2025-03-20 | View Filing |
| 10-K | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-12 | 2025-03-12 | View Filing |
| 8-K | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| SC 13G | 2025-02-04 | 2025-02-04 | View Filing |
| 8-K | 2025-01-28 | 2025-01-28 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 8-K | 2024-12-18 | 2024-12-18 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-10-01 | 2024-10-01 | View Filing |
| 8-K | 2024-09-13 | 2024-09-13 | View Filing |
| 8-K | 2024-08-28 | 2024-08-28 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-07-29 | 2024-07-29 | View Filing |
| 4 | 2024-06-11 | 2024-06-11 | View Filing |
| 4 | 2024-06-11 | 2024-06-11 | View Filing |
| 4 | 2024-06-11 | 2024-06-11 | View Filing |
| 4 | 2024-06-11 | 2024-06-11 | View Filing |
| 4 | 2024-06-11 | 2024-06-11 | View Filing |
| 4 | 2024-06-11 | 2024-06-11 | View Filing |
| 8-K | 2024-06-07 | 2024-06-07 | View Filing |
| 10-Q | 2024-05-07 | 2024-05-07 | View Filing |
| 8-K | 2024-05-07 | 2024-05-07 | View Filing |
| 4 | 2024-05-03 | 2024-05-03 | View Filing |
| ARS | 2024-04-26 | 2024-04-26 | View Filing |
| DEFA14A | 2024-04-26 | 2024-04-26 | View Filing |
| DEF 14A | 2024-04-26 | 2024-04-26 | View Filing |
| S-8 | 2024-03-26 | 2024-03-26 | View Filing |
| 10-K | 2024-03-26 | 2024-03-26 | View Filing |
| 8-K | 2024-03-26 | 2024-03-26 | View Filing |
| 4 | 2024-03-14 | 2024-03-14 | View Filing |
| 8-K | 2024-03-13 | 2024-03-13 | View Filing |
| 424B5 | 2024-03-13 | 2024-03-13 | View Filing |
| 8-K | 2024-03-11 | 2024-03-11 | View Filing |
| 424B5 | 2024-03-11 | 2024-03-11 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Neural Forcast | 40.46% | 1.01 | 936 | 0.03 | 0.05 | 37.27 |
| Williams PercentR Strategy | 20.32% | 1 | 432 | 0.01 | 0.04 | 17.14 |
| Triple MA | 18.96% | 1 | 562 | 0.02 | 0.05 | 15.77 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxx |
| xxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxx | xxxxx | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |